Meet Legend Biotech's new CEO Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 18 September, 2026

Real innovation is getting harder to spot. The Endpoints 11 is our read on the private companies clearing a rising bar, revealed at a gala dinner with the founders, investors and editors behind the list. Save on your gala pass with code ELEVEN26.

presented by Pac­ing the Jour­ney: A Frame­work to Com­mer­cial Readi­ness

SPOTLIGHT The most exciting biotech startups of 2026: How we selected this year's list

news Electra's $350M IPO will help it become a commercial biotech Peer Review Legend names new CEO as Carvykti competition grows; Vertex makes a flurry of moves Bristol Myers scraps $100M Orum-partnered cancer drug after reviewing Phase 1 data

Sep 22 12:00 pm ET The future of drug pricing: Medicare negotiation, MFN models & beyond sponsored by ADVI Oct 13 11:00 am ET Commercial excellence and AI - a ripple, wave or a tsunami sponsored by ZS Oct 15 1:00 pm ET Insights into Polycystic Kidney Disease: The Potential of Clinicogenomic Data sponsored by Natera Oct 20 11:00 am ET Intelligent oversight and orchestration: How mission control is redefining R&D decision-making sponsored by ZS Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel

AI has stopped being a question and started being an answer. Remaking workforces, AI-derived molecules into the clinic, catching record capital against sharpening doubt. What does it mean for biopharma? Find out, join us.

ENDPOINTS PHARMA Exclusive: Internal CMS email confirms Globe and Guard exemption strategy FDA approves Ultragenyx's gene therapy for Sanfilippo syndrome type A The realities of China’s prolific biotech rise are felt at FDA UK government committees call for probe into US pharma deal

in case you missed it 1. Reverse merger run extends as Marea, North Immunology line up deals with $405M in backing 2. Lilly-backed Orbis does up to $1.4B macrocycle deal with Novo 3. Roche turns to Dualitas to find new bispecific approaches for immunology 4. Bavarian Nordic names Tarja Stenvall as new CEO